Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
Recruiting now NCT04579900
Run by Laval University · for 18 to 60 · All sexes · accepts healthy volunteers
What this study is about
It is now well documented that changes in gut microbiota composition accompany obesity and type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it is known that hyperglycemia during T2D induces a more permissive gut barrier allowing increased penetration of microbes and their products into the blood. An important next step is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial components to subvert the gut barrier and alter glucose control. It is hypothesized that gut microbes in the colon and other lower gut segments are key modulators of energy balance, glucose homeostasis and insulin sensitivity.
Who can join (things the study team will check)
✅ You may be able to join if…
- T2DB de novo or non T2DB patients
🚫 You may not be able to join if…
- oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Where this trial is running
- INAF, Université Laval, Québec, Quebec, Canada
Who to contact
Geneviève Pilon, PhD · 418-656-8711 · Genevieve.Pilon@criucpq.ulaval.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04579900.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.